Table 2 Baseline characteristics of the study participants
| Â | Total | NHR group | HR group | P value |
|---|---|---|---|---|
Characteristics | (n = 12,966) | (n = 3118, 24.05%) | (n = 9848, 75.95%) | |
Age (years) | 63.90 ± 7.30 | 63.70 ± 7.30 | 63.96 ± 7.30 | 0.085 |
Gender | Â | Â | Â | <0.001 |
 Male | 5206 (40.20%) | 1150 (36.90%) | 4056 (41.20%) |  |
 Female | 7760 (59.80%) | 1968 (63.10%) | 5792 (58.80%) |  |
BMI (kg/m2)a | 25.10 ± 3.81 | 25.01 ± 3.78 | 25.14 ± 3.82 | 0.105 |
SBP (mmHg) | 135.80 ± 17.48 | 134.81 ± 16.88 | 136.11 ± 17.65 | <0.001 |
DBP(mmHg) | 82.25 ± 10.89 | 81.27 ± 10.49 | 82.56 ± 10.99 | <0.001 |
Uric Acid (mg/dl) | 5.51 ± 1.49 | 5.36 ± 1.42 | 5.56 ± 1.51 | <0.001 |
Creatinine (μmol/l) | 68.09 ± 25.86 | 66.39 ± 21.99 | 68.63 ± 26.95 | <0.001 |
Triglycerides (mmol/l) | 1.80 ± 1.43 | 1.76 ± 1.34 | 1.81 ± 1.45 | 0.086 |
Glucose (mmol/l) | 6.27 ± 2.03 | 6.24 ± 1.87 | 6.29 ± 2.07 | 0.261 |
Folic Acid (ng/ml) | 18.46 ± 14.70 | 17.99 ± 13.37 | 18.61 ± 15.09 | 0.044 |
DM | Â | Â | Â | 0.14 |
 No | 10,089 (80.70%) | 2466 (81.60%) | 7623 (80.40%) |  |
 Yes | 2412 (19.30%) | 555 (18.40%) | 1857 (19.60%) |  |
Study Center | Â | Â | <0.001 | Â |
 Anqing | 2319 (17.90%) | 420 (13.50%) | 1899 (19.30%) |  |
 Lianyungang | 10,647 (82.10%) | 2698 (86.50%) | 7949 (80.70%) |  |
Treatment Group | Â | Â | 0.985 | Â |
 Enalapril only | 6531 (50.40%) | 1571 (50.40%) | 4960 (50.40%) |  |
 Enalapril-Folic Acid | 6435 (49.60%) | 1547 (49.60%) | 4888 (49.60%) |  |
Smoker | Â | Â | Â | 0.15 |
 Never | 8697 (67.60%) | 2135 (69.00%) | 6562 (67.20%) |  |
 Former | 1404 (10.90%) | 316 (10.20%) | 1088 (11.10%) |  |
 Current | 2756 (21.40%) | 643 (20.80%) | 2113 (21.60%) |  |
Alcohol Consumption | Â | Â | Â | 0.001 |
 Never | 8733 (70.80%) | 2184 (73.40%) | 6549 (69.90%) |  |
 Former | 838 (6.80%) | 176 (5.90%) | 662 (7.10%) |  |
 Current | 2770 (22.40%) | 615 (20.70%) | 2155 (23.00%) |  |